ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'
ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology Technology excellence validated by winning first place at 'Novo Nordisk Partnering Day Korea 2026' SEOUL, South Korea, April 22, 2026...
ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a...